NURP.F Stock Overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.53 |
| 52 Week High | AU$17.21 |
| 52 Week Low | AU$6.17 |
| Beta | 1.99 |
| 1 Month Change | -6.53% |
| 3 Month Change | -19.94% |
| 1 Year Change | 32.94% |
| 3 Year Change | 1,116.50% |
| 5 Year Change | 1,332.00% |
| Change since IPO | 2,178.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| NURP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | 32.9% | 13.2% | 24.9% |
Return vs Industry: NURP.F exceeded the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: NURP.F exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| NURP.F volatility | |
|---|---|
| NURP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NURP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NURP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NURP.F fundamental statistics | |
|---|---|
| Market cap | US$1.56b |
| Earnings (TTM) | US$101.87m |
| Revenue (TTM) | US$150.42m |
15.3x
P/E Ratio10.4x
P/S RatioIs NURP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NURP.F income statement (TTM) | |
|---|---|
| Revenue | AU$231.94m |
| Cost of Revenue | AU$26.75m |
| Gross Profit | AU$205.19m |
| Other Expenses | AU$48.11m |
| Earnings | AU$157.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.23 |
| Gross Margin | 88.47% |
| Net Profit Margin | 67.72% |
| Debt/Equity Ratio | 0% |
How did NURP.F perform over the long term?
See historical performance and comparison